Industry
Biotechnology
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Loading...
Open
13.21
Mkt cap
170M
Volume
31K
High
13.55
P/E Ratio
-15.93
52-wk high
21.44
Low
12.90
Div yield
N/A
52-wk low
8.00
Portfolio Pulse from
November 18, 2024 | 11:15 am
Portfolio Pulse from Benzinga Newsdesk
August 23, 2024 | 11:50 am
Portfolio Pulse from Benzinga Newsdesk
August 01, 2024 | 10:06 am
Portfolio Pulse from Avi Kapoor
July 25, 2024 | 11:43 am
Portfolio Pulse from Benzinga Newsdesk
June 26, 2024 | 11:37 am
Portfolio Pulse from Benzinga Newsdesk
June 14, 2024 | 10:07 am
Portfolio Pulse from Benzinga Newsdesk
May 22, 2024 | 12:12 pm
Portfolio Pulse from Benzinga Insights
April 22, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
February 28, 2024 | 6:23 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.